A small randomized clinical trial suggests that a daily oral GLP-1 medication may reduce heavy drinking among people with alcohol use disorder. Researchers tested oral semaglutide, the active ingredient in drugs such as Ozempic and Wegovy, in a study that compared participants taking the GLP-1 pill with those receiving a placebo. According to reports, participants assigned to semaglutide experienced fewer days of heavy drinking than the placebo group, along with other reported improvements related to alcohol use. The findings are reported as being published in the American Journal of Psychiatry. The outlets describing the study emphasize that the trial is limited in size and that results should be interpreted cautiously, but they point to the possibility that GLP-1–based treatments could play a role in alcohol-use interventions. Overall, the coverage agrees that the trial finds a benefit signal for oral semaglutide in reducing heavy drinking days, while additional research would be needed to confirm effectiveness and determine long-term outcomes.